GOLDEN, Colo., Aug. 28, 2012 (GLOBE NEWSWIRE) -- Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, announced advances in the commercialization of its infertility treatment drug, Vitropin™, a highly purified form of FSH produced through Vitro Biopharma's patented production process. During 2011, Vitro licensed two of its patents and certain rights to other related intellectual property to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies (ART). Dr. Posillico and his team of professionals have recently begun the process of registration of Vitropin™ and related products in certain foreign markets. This registration is being pursued together with the establishment of a separate manufacturing contract and various distribution partnerships. Product marketing, distribution and sales will be managed by an international group of professionals that have considerable expertise in the distribution of similar products in the ART feild. The development plan also contemplates registrations for marketing approval of Vitropin™ in several additional countries including the US and EU that collectively represent a multi-billion dollar market.
